Clinical Trial: NCT06513364
Neoadjuvant Chemotherapy With WH002 in Women With HER2-negative Breast Cancer
Status:
COMPLETEDPhase:
Phase 2| Lead Sponsor: | Beijing Wehand-Bio Pharmaceutical Co., Ltd |
| Information Provided By: | Beijing Wehand-Bio Pharmaceutical Co., Ltd |
| Last Update Posted: | 2026-06-09 |
Study Overview
Brief Summary
The purpose of this study is to compare the safety and efficacy of bi-weekly WH002(Paclitaxel Medium and Long Chain Fat Emulsion Injection,Cholesterol Bound) vs Paclitaxel both followed by bi-weekly Epirubicin and Cyclophosphamide as neoadjuvant treatment in women with HER2-negative breast cancer.
Official Title
A Phase II Randomized Parallel Study of Comparing WH002 With Paclitaxel Both Sequential of Epirubicin and Cyclophosphamide As Neoadjuvant Treatment of Women With HER2-Negative Breast Cancer
Conditions
Breast Cancer
Intervention / Treatment
- Drug: WH002
- Drug: paclitaxel injection
Other Study ID Numbers
- WH002-I-102
Start Date (Actual)
2024-09-10
Primary Completion Date (Actual)
2025-08-15
Study Completion Date (Actual)
2025-11-17
Enrollment (Actual)
40
Study Type
Interventional
Phase
Phase 2
| Lead Sponsor: | Beijing Wehand-Bio Pharmaceutical Co., Ltd |
| Information Provided By: | Beijing Wehand-Bio Pharmaceutical Co., Ltd |
| Last Update Posted: | 2026-06-09 |
Study Overview
Brief Summary
The purpose of this study is to compare the safety and efficacy of bi-weekly WH002(Paclitaxel Medium and Long Chain Fat Emulsion Injection,Cholesterol Bound) vs Paclitaxel both followed by bi-weekly Epirubicin and Cyclophosphamide as neoadjuvant treatment in women with HER2-negative breast cancer.
Official Title
A Phase II Randomized Parallel Study of Comparing WH002 With Paclitaxel Both Sequential of Epirubicin and Cyclophosphamide As Neoadjuvant Treatment of Women With HER2-Negative Breast Cancer
Conditions
Breast Cancer
Intervention / Treatment
- Drug: WH002
- Drug: paclitaxel injection
Other Study ID Numbers
- WH002-I-102
Start Date (Actual)
2024-09-10
Primary Completion Date (Actual)
2025-08-15
Study Completion Date (Actual)
2025-11-17
Enrollment (Actual)
40
Study Type
Interventional
Phase
Phase 2